▍ Author /Ania
65.438+0.2 billion yuan, and then Ding Medicine introduced new varieties.
Recently, Zaiding Medicine, a listed company in the US stock market, announced that it has reached an authorization agreement with Turning Point Therapeutics, an anti-cancer drug research and development company, on a new generation of tyrosine kinase inhibitor Repotrectinib. According to the agreement, Zaiding Medicine will obtain the exclusive R&D and commercialization rights of Repotrectinib in Greater China. The total amount of this transaction is as high as US$ 654.38+76 billion (RMB 654.38+23.3 million in total).
According to the agreement, Turning Point Therapeutics will receive a cash advance of US$ 25 million, as well as a potential development, registration and sales-based milestone payment with a total price of US$ 65,438 +0.565 billion. In addition, Zaiding Medicine will pay the patent fee to Turning Point according to the annual net sales of Repotrectinib in Greater China.
Repotrectinib is a new generation kinase inhibitor under study, which is aimed at treating non-small cell lung cancer and advanced solid tumor caused by the changes of ROS 1 and TRK oncogene. The second phase of registration research is being carried out around the world.
The data show that Repotrectinib can effectively target ROS 1 and TRK A/B/C, and has therapeutic potential for patients who have not received TKI treatment or have received TKI treatment. In China, ROS 1 rearrangement, as the driving gene change of carcinogenesis, accounts for about 2% to 3% of patients with advanced non-small cell lung cancer, and NTRK accounts for about 0.5% of patients with other advanced solid tumors.
Lung cancer is one of the most common malignant tumors, and its mortality rate has always ranked first among all cancers. Non-small cell lung cancer includes ordinary adenocarcinoma, squamous cell carcinoma and alveolar carcinoma. The 5-year survival rate after early (multi-fingered stage I) radical operation is about 45%.
If Repotrectinib can be commercialized quickly, there will be a great market space to be tapped.
Zaiding Pharmaceutical was established on 20 14 and headquartered in Shanghai. It is an innovative biopharmaceutical company dedicated to providing innovative drugs in the fields of cancer, autoimmune and infectious diseases. 2065438+September 2007, Zaiding Medicine landed on Nasdaq; In 20 19, the company's tumor drug "Zele" (rapali toluene sulfonic acid capsule) and tumor treatment system "Epudun" (tumor electric field therapy) were successfully listed in Hongkong, China. In 2020, Lele will be officially commercialized in Chinese mainland.
The 20 19 annual report of Zaiding Pharmaceutical shows that its annual revenue is130,000 US dollars, up by 129 times year-on-year. The revenue mainly comes from Zele and Epdun-Zele's sales revenue in Chinese mainland, Hongkong and Macau is 6.6 million US dollars, and EPDUN's sales revenue is 6.4 million US dollars.
It is worth mentioning that these two drugs were introduced by Re-Ding Medicine on 1996.
Zele (Ni Rapali) is a selective poly (ADP- ribose) PARP 1/2 inhibitor developed by TESARO, a subsidiary of GlaxoSmithKline. It is used for maintenance treatment of patients with recurrent epithelial ovarian cancer, tubal cancer or primary peritoneal cancer who are completely or partially relieved by platinum-containing chemotherapy. In fact, it is the first one in the world to be approved for patients with platinum-sensitive recurrent ovarian cancer.
In 20 16, Zaiding Medicine signed an agreement with Tesaro in, and obtained the exclusive R&D and sales rights of Ni Rapali in China market. According to IQVIA data, Zelle is now the PARP inhibitor with the highest market share in Hong Kong, and the market share of 20 19 reached 77% in the third quarter.
In addition, on 20 18, Novocure and Zaiding Medicine announced an agreement on the exclusive commercial license and global strategic development cooperation of tumor electric field therapy (TTF) in Greater China. Huaxing Capital is the exclusive financial advisor of Novocure Company in this transaction.
At the end of 2065438+2008, Appleton was successfully listed in Hongkong, China for the treatment of recurrent and newly diagnosed glioblastoma patients.
In fact, License in is the core business model of Redding at present, and it has launched a variety of products through a number of licensing cooperation:
For example, the three monoclonal antibodies in the study are from MacroGenics, durlobactam, a new antibiotic from Entasis, and NiRapali, a PARP 1/2 inhibitor from GlaxoSmithKline ... The high-quality products launched with unique vision have indeed brought rich income to Reding Medicine after commercialization.
According to the data, in the product pipeline of Reding Pharmaceutical, five drugs have obtained implied permission for clinical trials in China this year, including PD- 1 monoclonal antibody INCMGA000 12 injection, HER2 monoclonal antibody margetuximab injection and PD- 1/ LAG-3 bispecific antibody MGD0/kloc.
It is understood that since the establishment of Zaiding Pharmaceutical in 20 14 years, 15 candidate drugs have been listed in IN in a licensed way, and more than 20 clinical trials are under way or planned, and more than half of the research pipelines have entered the third phase clinical trials.
Although we can expand our product pipeline by taking the lead in introducing foreign advanced research results, we can enter the market at the first time and gain the advantage of heavy volume; However, it should be noted that the cash flow of enterprises will face greater impact, because the way of authorization is to buy the development rights and commercialization rights of products from other companies at great cost.
According to the financial data of Zaiding Pharmaceutical, from 20 17 to 20 19, the net cash flow of the company's investment activities was-10434200 USD,-2130000 USD and-1489200 USD respectively.